FCG Investment Co Buys 5,777 Shares of Johnson & Johnson (NYSE:JNJ)

Key Points

• FCG Investment Co has increased its holdings in Johnson & Johnson (NYSE: JNJ) by 56.3% during the first quarter, now owning a total of 16,043 shares valued at approximately $2.66 million.
• Johnson & Johnson reported a $2.77 EPS for the last quarter, exceeding analysts' expectations and generating a revenue of $23.74 billion, reflecting a year-over-year growth of 5.8%.
• The company announced a quarterly dividend of $1.30 per share, with an annualized dividend yield of 2.9%, set to be paid on September 9th.

FCG Investment Co raised its holdings in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 56.3% in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 16,043 shares of the company's stock after purchasing an additional 5,777 shares during the quarter. Johnson & Johnson accounts for about 1.7% of FCG Investment Co's portfolio, making the stock its 15th largest position. FCG Investment Co's holdings in Johnson & Johnson were worth $2,661,000 as of its most recent SEC filing.

Several other institutional investors have also bought and sold shares of the business. Elios Financial Group Inc. raised its stake in shares of Johnson & Johnson by 1.5% in the first quarter. Elios Financial Group Inc. now owns 4,496 shares of the company's stock valued at $746,000 after acquiring an additional 66 shares during the period. Atlantic Family Wealth LLC raised its stake in shares of Johnson & Johnson by 4.4% in the first quarter. Atlantic Family Wealth LLC now owns 1,603 shares of the company's stock valued at $266,000 after acquiring an additional 67 shares during the period. MBA Advisors LLC raised its stake in shares of Johnson & Johnson by 1.2% in the first quarter. MBA Advisors LLC now owns 5,553 shares of the company's stock valued at $921,000 after acquiring an additional 68 shares during the period. Sovereign Financial Group Inc. raised its stake in shares of Johnson & Johnson by 1.8% in the first quarter. Sovereign Financial Group Inc. now owns 3,928 shares of the company's stock valued at $651,000 after acquiring an additional 69 shares during the period. Finally, Nabity Jensen Investment Management Inc raised its stake in shares of Johnson & Johnson by 1.5% in the first quarter. Nabity Jensen Investment Management Inc now owns 4,624 shares of the company's stock valued at $767,000 after acquiring an additional 69 shares during the period. Institutional investors own 69.55% of the company's stock.

Johnson & Johnson Stock Up 1.2%

JNJ stock opened at $176.76 on Friday. The firm has a 50 day moving average of $161.28 and a 200 day moving average of $158.39. The stock has a market capitalization of $425.70 billion, a PE ratio of 18.90, a price-to-earnings-growth ratio of 2.25 and a beta of 0.41. The company has a quick ratio of 0.76, a current ratio of 1.01 and a debt-to-equity ratio of 0.50. Johnson & Johnson has a 52 week low of $140.68 and a 52 week high of $177.27.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last released its earnings results on Wednesday, July 16th. The company reported $2.77 EPS for the quarter, topping analysts' consensus estimates of $2.68 by $0.09. The company had revenue of $23.74 billion during the quarter, compared to analysts' expectations of $22.85 billion. Johnson & Johnson had a net margin of 25.00% and a return on equity of 32.49%. Johnson & Johnson's revenue for the quarter was up 5.8% on a year-over-year basis. During the same period last year, the business earned $2.82 EPS. Sell-side analysts forecast that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 9th. Shareholders of record on Tuesday, August 26th will be paid a dividend of $1.30 per share. This represents a $5.20 annualized dividend and a yield of 2.9%. The ex-dividend date is Tuesday, August 26th. Johnson & Johnson's payout ratio is presently 55.61%.

Analysts Set New Price Targets

JNJ has been the topic of several recent analyst reports. Leerink Partnrs downgraded shares of Johnson & Johnson from a "strong-buy" rating to a "hold" rating in a research note on Tuesday, May 13th. Leerink Partners downgraded shares of Johnson & Johnson from an "outperform" rating to a "market perform" rating and reduced their price target for the stock from $169.00 to $153.00 in a research note on Tuesday, May 13th. Bank of America raised their price target on shares of Johnson & Johnson from $161.00 to $175.00 and gave the stock a "neutral" rating in a research note on Thursday, July 17th. Royal Bank Of Canada raised their price target on shares of Johnson & Johnson from $181.00 to $185.00 and gave the stock an "outperform" rating in a research note on Thursday, July 17th. Finally, Benchmark raised shares of Johnson & Johnson to a "strong-buy" rating in a research note on Thursday, April 24th. Nine investment analysts have rated the stock with a hold rating, ten have assigned a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $174.50.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.